TG Therapeutics, Inc. TGTX
- Market cap
- $8.8B
- P/E
- 18.9×
Follow TGTX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 4.10 | 3.32 | 3.87 | 6.34 | 12.62 | 3.48 | 6.46 | 12.84 | 25.28 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 11.76 | 15.35 | 17.35 | 11.42 | 56.11 | 56.74 | 20.69 | 35.67 | 36.84 | 46.48 |
High Price
|
|||
| 64 | 75 | 105 | 134 | 272 | 286 | 226 | 264 | 338 | 399 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
Revenue/Emp
|
|||
| 0 | 0 | 0 | 0 | 0 | 7 | 3 | 234 | 329 | 616 |
Revenue
|
|||
| 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 88.19% | 90.48% | 93.95% | 88.30% | 83.66% |
Gross Margin
|
|||
| (78) | (118) | (173) | (173) | (279) | (348) | (224) | 13 | 26 | 107 |
EBT
|
|||
| (51,482.24%) | (77,944.74%) | (114,132.89%) | (113,730.92%) | (183,803.29%) | (5,204.08%) | (8,036.34%) | 5.59% | 7.78% | 17.43% |
EBT Margin
|
|||
| (78) | (118) | (173) | (173) | (279) | (348) | (224) | 13 | 23 | 447 |
Net Income
|
|||
| 1 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | (5) | (2) |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.02 | 1.65 | 2.26 | 4.27 |
Revenue/Sh
|
|||
| (1.60) | (1.91) | (2.15) | (1.96) | (2.42) | (2.63) | (1.46) | 0.09 | 0.16 | 3.10 |
Earnings/Sh
|
|||
| (1.26) | (1.51) | (1.71) | (1.50) | (1.86) | (2.24) | (1.30) | (0.22) | (0.28) | (0.17) |
Cash Flow/Sh
|
|||
| (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (1.26) | (1.51) | (1.71) | (1.50) | (1.86) | (2.24) | (1.30) | (0.22) | (0.28) | (0.17) |
Free CF/Sh
|
|||
| 0.73 | 1.08 | 0.32 | 0.44 | 4.50 | 1.79 | 0.43 | 1.13 | 1.53 | 4.49 |
Book Value/Sh
|
|||
| 49 | 62 | 75 | 88 | 115 | 132 | 135 | 142 | 145 | 144 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 213.00 | 177.06 | 9.71 |
PE Ratio
|
|||
| 1,435.74 | 3,573.11 | 2,035.62 | 6,453.26 | 39,471.54 | 375.58 | 562.55 | 10.35 | 13.29 | 6.98 |
PS Ratio
|
|||
| 6.08 | 8.11 | 12.87 | 25.40 | 11.55 | 10.59 | 26.74 | 15.07 | 19.67 | 6.64 |
PB Ratio
|
|||
| 1,141.20 | 3,016.52 | 1,583.09 | 5,731.82 | 35,702.31 | 338.65 | 530.61 | 9.86 | 13.10 | 7.15 |
EV/Sales
|
|||
| (2.80) | (4.89) | (1.87) | (6.55) | (25.26) | (7.65) | (8.39) | (73.28) | (106.21) | (176.39) |
EV/FCF
|
|||
| (62) | (94) | (129) | (133) | (215) | (296) | (176) | (31) | (41) | (25) |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
Capex
|
|||
| (62) | (94) | (129) | (133) | (215) | (296) | (176) | (31) | (41) | (25) |
FCF
|
|||
| 34 | 65 | 40 | 65 | 524 | 266 | 115 | 264 | 476 | 477 |
Working Cap'
|
|||
| 0 | 0 | 0 | 31 | 33 | 68 | 73 | 100 | 244 | 246 |
Total Debt
|
|||
| (45) | (85) | (69) | (110) | (573) | (247) | (89) | (117) | (67) | 104 |
Net Debt
|
|||
| 36 | 67 | 24 | 39 | 519 | 237 | 59 | 161 | 222 | 648 |
Sh' Equity
|
|||
| (93.02%) | (155.72%) | (191.70%) | (140.19%) | (70.85%) | (69.26%) | (78.09%) | 4.84% | 5.15% | 54.50% |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 29.91% | 16.82% | 10.25% |
ROIC
|
|||
| (113.87%) | (230.36%) | (381.16%) | (551.85%) | (100.14%) | (92.03%) | (151.36%) | 11.57% | 12.21% | 102.75% |
ROE
|
|||
TG Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PTGX Protagonist Therapeutics, Inc. | $8.9B | 117× | Compare |
| CYTK Cytokinetics, Incorporated | $9.0B | 0.0× | Compare |
| CAI Caris Life Sciences,�Inc. | $9.1B | 85.1× | Compare |
| PCVX Vaxcyte, Inc. | $8.5B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IBRX ImmunityBio, Inc. | $9.2B | 0.0× | Compare |
| ARWR Arrowhead Pharmaceuticals, Inc. | $9.3B | 0.0× | Compare |
| ABVX Abivax SA Sponsored ADR | $8.2B | 0.0× | Compare |
| KYMR Kymera Therapeutics, Inc. | $9.7B | 0.0× | Compare |
TG Therapeutics, Inc. (TGTX) key facts
- TG Therapeutics, Inc. (TGTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- As of September 25, 2026, TGTX traded at $57.43, a market capitalization of $8.8 billion.
- Return on equity was 102.8% and debt-to-equity 1.23.
TG Therapeutics, Inc. (TGTX) Latest News
18 Sep
TG Therapeutics targets $1B annual run rate as BRIUMVI gains multiple sclerosis market share. BRIUMVI market share expansion positions TG Therapeutics for major revenue growth and trajectory shift.
16 Sep
TG Therapeutics executed a bullish strategic move in ongoing competition with Roche. Bullish move by TG Therapeutics strengthens competitive position versus Roche and may significantly shift market trajectory.
2 Sep
TG Therapeutics (TGTX) is named IBD Stock of the Day and shows potential to break out after topping its early buy point. Positive technical breakout signal and IBD spotlight can moderately lift near-term investor interest and stock movement.
21 Aug
TG Therapeutics stock heads for best day in 3.5 months driven by fresh buyout rumors. Buyout rumors signal possible acquisition that could reshape company ownership and valuation.
Takeover rumors are swirling around TG Therapeutics (TGTX), triggering stock alerts and investor focus on potential acquisition scenarios that could reshape the company's ownership and valuation. Takeover rumors signal possible major ownership shifts with direct effects on TGTX trajectory and investor sentiment.
10 Aug
TG Therapeutics held its Q2 2026 earnings call, covering financial results, operational updates, and future outlook for the company. Q2 earnings results and guidance directly affect stock price and investor outlook for TG Therapeutics.
4 Aug
TG Therapeutics raised revenue guidance, indicating the stock may be undervalued. Rising revenue guidance signals stronger financial outlook and potential revaluation for TG Therapeutics.
TG Therapeutics raised guidance yet shares suffered sharp pullback, prompting debate over whether the stock is now a bargain. Higher guidance signals improved operational outlook for TG Therapeutics while pullback may shift near-term investor sentiment and valuation.
TG Therapeutics, Inc. held its Q2 2026 earnings call covering financial results and company outlook. Quarterly earnings calls deliver performance updates that moderately influence investor sentiment and near-term stock movement.
TG Therapeutics missed Q2 estimates, triggering a 15.9% stock drop, but raised its 2026 outlook. Q2 miss paired with raised 2026 guidance creates mixed moderate effects on near-term performance and sentiment.
3 Aug
TG Therapeutics CEO states Briumvi is on track to become a $1B US drug while retail investors ignore an EPS miss. Briumvi sales forecast points to major revenue growth and trajectory shift for TG Therapeutics.
TG Therapeutics raises 2026 outlook after strong Briumvi sales growth. Raised 2026 outlook after strong Briumvi sales signals major positive shift in financial trajectory and investor outlook.
TG Therapeutics reported second quarter 2026 financial results and raised BRIUMVI revenue guidance. Raised BRIUMVI revenue guidance signals stronger product sales and improved growth outlook.
TG Therapeutics posted Q2 earnings below expectations while sales rose year over year; the company raised its 2026 outlook but shares declined. Mixed Q2 results with raised 2026 guidance point to limited net change in company trajectory.
TG Therapeutics held its Q2 earnings call, covering financial results, operational updates, product pipeline progress, and forward-looking guidance for the company. Q2 earnings details and highlights directly inform investors on financial results and strategic outlook.
TG Therapeutics (TGTX) Q2 earnings key metrics are analyzed to assess company performance and financial standing. Q2 earnings metrics analysis can moderately shift investor sentiment on TG Therapeutics financial results.
TG Therapeutics (TGTX) missed Q2 earnings estimates. Missing quarterly earnings estimates can pressure TG Therapeutics stock price and near-term investor sentiment.
13 Jul
TG Therapeutics stock rises after its key drug surpasses performance expectations. Positive results on a key drug signal strong future revenue and stock performance for TG Therapeutics.
9 Jul
TG Therapeutics shares may remain undervalued after new clinical trial updates, with analysis indicating potential upside despite recent developments in its pipeline. New trial data can influence sentiment and valuation but appears balanced by ongoing market perceptions of limited immediate trajectory change.
8 Jul
TG Therapeutics launches schizophrenia trial for BRIUMVI to test expansion beyond its current multiple sclerosis indication. Schizophrenia trial success could expand BRIUMVI into large new market and shift company trajectory.
TG Therapeutics released a schizophrenia trial update that questions whether the stock trades at full value. Schizophrenia trial data may shift near-term sentiment and valuation without altering core MS or oncology trajectory.
7 Jul
TG Therapeutics shares rise after analysts hike price targets and the company launches a new schizophrenia clinical trial. Price target increases lift near-term sentiment while schizophrenia trial entry signals pipeline expansion beyond oncology.
TG Therapeutics initiates Phase II study of Briumvi in schizophrenia. Phase II schizophrenia trial expands Briumvi into new indication with moderate long-term upside.
6 Jul
TG Therapeutics initiates Phase 2 trial evaluating BRIUMVI in patients with treatment-resistant schizophrenia. Phase 2 start in new schizophrenia indication offers moderate market expansion potential for BRIUMVI beyond MS.
3 Jul
Briumvi sales strength may boost TG Therapeutics revenue in Q2 amid ongoing market competition and product adoption trends. Briumvi performance directly influences quarterly revenue and investor views on TGTX growth.
17 Jun
TG Therapeutics (TGTX) stock extends rally through eighth straight session on release of new BRIUMVI clinical data. New BRIUMVI clinical data drives sustained rally and directly supports product advancement and market positioning.
TG Therapeutics stock surges 70% on strong momentum, with shares continuing to climb amid positive developments driving investor interest. 70% stock surge reflects major positive shift likely to boost future valuations and sentiment for TG Therapeutics.
10 Jun
TG Therapeutics advances at-home subcutaneous BRIUMVI for MS treatment, driving 18.4% stock rise. Subcutaneous BRIUMVI advancement expands TG Therapeutics core MS product reach and adoption potential.
TG Therapeutics (TGTX) stock breaks out to a four-year high and is named IBD Stock of the Day as a Roche rival. Four-year high breakout improves short-term sentiment and visibility but does not alter fundamentals or competitive positioning.
TG Therapeutics stock rises after reporting positive Phase I data for subcutaneous Briumvi in Myasthenia Gravis. Positive early-stage data supports moderate pipeline expansion potential for approved drug Briumvi.